Léiríonn taighde New Clinic Cleveland don chéad uair go bhféadfadh ibrutinib (ibrutinib) atá ceadaithe ag FDA le haghaidh liomfóma agus leoicéime cabhrú freisin le cóireáil a dhéanamh ar na siadaí inchinn is coitianta agus deadly, agus féadfar lá amháin a úsáid in othair le glioblastoma Agus feabhas a chur ar rátaí marthanais.
De réir tuarascála ón gCumann Meiriceánach Brain Tumor, tá an ráta marthanais glioblastoma an-íseal, agus tá marthanais meánach na n-othar a fhaigheann cóireáil chaighdeánach níos lú ná 15 mhí. Is é Glioblastoma an meall inchinn bunscoile is marfach agus tá sé an-resistant do chóireálacha reatha. Tá géarghá le cóireálacha nua a chur ar fáil do na hothair seo chomh luath agus is féidir.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain siadaí in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
